• Steel and Composite Structures
• /
• 제23권1호
• /
• pp.131-142
• /
• 2017

Determining limit load for a pressure bearing structure using elastic-plastic finite element analysis was computationally very expensive. A series of robust methods using elastic modulus adjustment techniques (EMAP) to identify the limit load directly were proposed. The numerical implementation of the robust method had the potential to be an attractive alternative to elastic-plastic finite element analysis since it was simple, and required less computational effort and computer storage space. Another attractive feature was that the method provided a go/no go criterion for the limit load, whereas the results of an elastic-plastic analysis were often difficult to interpret near the limit load since it came from human sources. To explore the performance of the method further, it was applied to a number of configurations that include two-dimensional and three-dimensional effects. In this study, limit load of cylinder with nozzle was determined by the robust methods.

• Molecules and Cells
• /
• 제21권2호
• /
• pp.213-217
• /
• 2006

Although AIMP1 (previously known as p43) is one of three auxiliary proteins bound to a macromolecular aminoacyl tRNA complex, it is also secreted as a cytokine controlling both angiogenesis and immune responses. Here we show that systemically administered purified recombinant human AIMP1 had anti-tumor activity in mouse xenograft models. In Meth A-bearing Balb/c mice, tumor volume increased about 28 fold in the vehicle treatment group, while an increase of about 16.7 fold was observed in the AIMP1-treated group. We also evaluated the anti-tumor activity of AIMP1 in combination with a sub-clinical dose of the cytotoxic anti-tumor drug, paclitaxel. The growth of NUGC-3 human stomach cancer cells was suppressed by 84% and 94% by the combinations of 5 mg/kg paclitaxel + 25 mg/kg AIMP1 (p = 0.03), and 5 mg/kg paclitaxel + 50 mg/kg AIMP1 (p = 0.02), respectively, while 5 mg/kg paclitaxel alone suppressed growth by only 54% (p = 0.02). A similar cooperative effect of AIMP1 and paclitaxel was observed in a lung cancer xenograft model. These results suggest that AIMP1 may be useful as a novel anti-tumor agent.